Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

To truly shift the landscape in obesity care, explains Jaime Almandoz, MD, MBA, UT Southwestern, care models and policies must also consider quality of life and total health outcomes.

Global type 1 diabetes cases are on the rise, especially in low-income countries, highlighting an urgent need for targeted health care strategies and epidemiological studies.

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 Vibrance-MG study investigator, he explains the difficulty of evaluating investigative treatments for pediatric patients who have myasthenia gravis.

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking financial stability and patient access to care.

Combining FRAX and MG-ADL assessments enhances fracture risk prediction in patients with myasthenia gravis (MG), guiding targeted interventions for better outcomes.

Exploring caregiver dependence and social determinants of health reveals critical barriers to HIV care for children, impacting treatment adherence and access, explains Priscilla Tsondai, MD, MPH.

Findings from surveys of women with pulmonary arterial hypertension (PAH) include that 20% of health care providers were viewed as dismissive because of the patient’s sex.

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, speaks about the clinical and operational priorities that academic medical centers make front-and-center when caring for underserved populations receiving treatment for cancer.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.

The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for minimal residual disease.

A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia gravis (gMG), behind the February EU approval of 2 self-administration approvals for the neonatal Fc receptor monoclonal antibody: an infusion pump and manual push with a syringe.

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding of the biologic rationale for various treatments, explained ECHELON-3 principal investigator Craig A. Portell, MD, of UVA Health.

"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains Jonathan Strober, MD, pediatric neurologist with UCSF Benioff Children's Hospital.

Proposed Medicaid cuts in the Republican budget proposal hold significant implications for health care access and coverage.

The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.

Experts at the Community Oncology Conference discuss innovative patient navigation programs, emphasizing technology's role and the importance of human connection in cancer care.

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discussed the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the need for equitable treatment strategies.

Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older adults.

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera.